Bain Capital said to weigh sale. Amsterdam IPO of Ahlstrom

Bain Capital said to weigh sale. Amsterdam IPO of Ahlstrom

Amsterdam, July 2, 2025 — Private equity firm Bain Capital is reportedly considering the sale of Ahlstrom, a global leader in specialty papers and packaging, through an initial public offering (IPO) in Amsterdam. The potential IPO comes amidst a surge in investor interest in medtech companies leveraging artificial intelligence (AI) for healthcare, as evidenced by the recent successful debut of Heartflow Inc. [1]

Heartflow Inc., a medtech firm backed by Bain Capital, made its Nasdaq debut on August 8, 2025, with a valuation of $2.27 billion. The company's shares surged 47.4% on the first day, opening at $28 and reaching a high of $31.5. The robust performance reflects investor appetite for AI-driven healthcare solutions [1].

The success of Heartflow's IPO has boosted market sentiment for other medtech companies, which often face significant research and development expenditures and clinical testing challenges. However, recent medtech IPOs have seen underwhelming post-listing performance, with many trading below their initial public offering prices [1].

Ahlstrom, founded in 1851, is a global player in the specialty papers and packaging sector. The company's extensive product portfolio includes products used in various industries such as packaging, hygiene, and technical applications. The potential IPO in Amsterdam could provide Ahlstrom with access to a new pool of investors and capital, potentially driving growth and innovation in the specialty papers market.

Bain Capital's decision to weigh the sale of Ahlstrom through an IPO in Amsterdam is a strategic move that capitalizes on the current market sentiment and investor interest in medtech and other tech-focused companies. The IPO market has shown resilience, with a number of successful debuts in recent months, despite concerns about trade policies and interest rates [1].

The potential IPO of Ahlstrom is a significant development for the specialty papers and packaging industry, as it could bring new investment and opportunities for growth. Investors and financial professionals will be closely monitoring the progress of the IPO, as it could set a precedent for other companies in the sector.

References:
[1] Reuters. (2025, August 8). Bain Capital-backed Heartflow valued at $2.27 billion in Nasdaq debut. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/bain-capital-backed-heartflow-valued-227-billion-solid-nasdaq-debut-2025-08-08/